Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings

Organigram Announces Mailing of Management Information Circular in Connection with Annual General and Special Meeting

By The Northwire Desk — AI Analysis Mar 10, 2026 · 06:00 OGI · 1.96 ORGANIGRAM GLOBAL INC.
OGI · Price

Executive Summary

  • Organigram Global Inc. is seeking shareholder approval at a special meeting on March 30, 2026 to acquire all outstanding shares of Sanity Group GmbH.
  • The transaction includes an upfront purchase price of €113.4 million (≈ €80 m cash + €33.4 m in Organigram common or Class A preferred shares) plus a potential earn‑out of up to €113.8 million based on Sanity’s post‑closing performance.
  • A concurrent private placement with British American Tobacco will raise C$65.2 million (14,027,074 shares at $3.00 each, plus top‑up rights for 9,897,356 shares) to fund the cash portion of the acquisition and related expenses.

Key Details

  • Transaction Resolution: Approval of Share Purchase Agreement dated Feb 18 2026 for purchase of Sanity Group’s issued and outstanding shares not already owned.
  • Purchase Price: €80 m cash + €33.4 m in Organigram equity at $3.00 per share (71% premium to the prior day’s TSX closing price of $1.75).
  • Earn‑out Component: Up to €20 m cash and €93.8 m in shares, contingent on Sanity Group’s financial performance during the 12 months following closing.
  • Closing Conditions: Subject to TSX approval, NASDAQ notification, German foreign direct investment clearance, and shareholder vote at the meeting.
  • Private Placement Financing (BAT):
  • Subscription for 14,027,074 Organigram shares at $3.00 per share.
  • Additional top‑up rights for 9,897,356 shares.
  • Gross proceeds of C$65.2 million.
  • Proceeds earmarked to fund the cash portion of the Sanity acquisition and transaction‑related expenses.
  • Meeting Details: Held in person at 333 Bay Street, Toronto on March 30, 2026, 10:00 a.m. ET; audio‑only conference available for remote shareholders (no voting via audio). Shareholder record date is Feb 23, 2026; proxy deadline March 26, 2026.
  • Board & Investment Committee Recommendation: Unanimous recommendation to vote in favour of the transaction, citing strategic expansion into Europe, vertical integration, financial accretion, and brand/IP synergies.
  • Strategic Rationale Highlights:
  • Entry into Germany (second‑largest legal cannabis market) and broader European footprint (UK, Switzerland, Poland).
  • Access to Sanity’s commercial network and regulatory expertise.
  • Expected revenue growth: Sanity’s net revenue rose from €9 m in 2023 to €60 m in 2025; gross margins improved from 15% to 47%.
  • Immediate Swiss retail presence via two pilot locations.

Notable Quotes

  • “The Transaction accelerates Organigram’s expansion into global cannabis markets by establishing a leading position in Germany, the world’s second‑largest federally legal cannabis market after Canada.” – Investment Committee & Board (paraphrased)

All forward‑looking statements are subject to risks and uncertainties detailed in the company’s circular and filings.

Read the original news release →

More from ORGANIGRAM GLOBAL INC.

May 14, 2026 · 08:45

Organigram Left Watching as European Cannabis Boom Accelerates, Q2 Miss Deepens Share Slide

M&A / Property May 12, 2026 · 06:00

Organigram’s core Canadian business stumbles into the red just as its landmark Sanity Group deal closes, leaving investors to wonder if the European cure will be enough to offset domestic decay.

Earnings Apr 15, 2026 · 12:03

Organigram Executes Europe Pivot as BAT Deal Closes, Dilution Looms

Financings Mar 30, 2026 · 20:30

Organigram Clears Final Hurdle for Sanity Acquisition as Dilution and Cash Constraints Loom

Financings Mar 23, 2026 · 14:07

Organigram garners ISS support for Sanity transaction

M&A / Property Mar 23, 2026 · 06:00

Organigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbH

M&A / Property